Vinva Investment Management Ltd Buys Shares of 1,950 Blueprint Medicines Co. (NASDAQ:BPMC)

Vinva Investment Management Ltd purchased a new stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC) in the 4th quarter, Holdings Channel reports. The fund purchased 1,950 shares of the biotechnology company’s stock, valued at approximately $170,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Xponance Inc. increased its position in shares of Blueprint Medicines by 12.3% during the fourth quarter. Xponance Inc. now owns 4,781 shares of the biotechnology company’s stock valued at $417,000 after acquiring an additional 525 shares in the last quarter. Intech Investment Management LLC increased its position in shares of Blueprint Medicines by 70.6% during the fourth quarter. Intech Investment Management LLC now owns 31,571 shares of the biotechnology company’s stock valued at $2,754,000 after acquiring an additional 13,060 shares in the last quarter. William Blair Investment Management LLC increased its position in shares of Blueprint Medicines by 16.1% during the fourth quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company’s stock valued at $169,616,000 after acquiring an additional 269,896 shares in the last quarter. Cibc World Markets Corp bought a new stake in shares of Blueprint Medicines during the fourth quarter valued at approximately $519,000. Finally, Swiss National Bank increased its position in shares of Blueprint Medicines by 7.2% during the fourth quarter. Swiss National Bank now owns 124,600 shares of the biotechnology company’s stock valued at $10,868,000 after acquiring an additional 8,400 shares in the last quarter.

Blueprint Medicines Stock Up 0.3 %

BPMC opened at $88.72 on Friday. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. Blueprint Medicines Co. has a fifty-two week low of $80.68 and a fifty-two week high of $121.90. The firm’s fifty day moving average is $99.47 and its 200 day moving average is $93.88. The stock has a market cap of $5.67 billion, a price-to-earnings ratio of -82.15 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, sell-side analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on BPMC shares. Scotiabank initiated coverage on shares of Blueprint Medicines in a research report on Friday, March 7th. They set a “sector outperform” rating and a $150.00 price target for the company. StockNews.com cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Monday, March 3rd. JPMorgan Chase & Co. raised their target price on shares of Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. JMP Securities restated a “market outperform” rating and issued a $125.00 target price on shares of Blueprint Medicines in a report on Friday, February 14th. Finally, Stephens restated an “overweight” rating and issued a $140.00 target price on shares of Blueprint Medicines in a report on Thursday, January 2nd. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $124.95.

Insider Activity at Blueprint Medicines

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 15,161 shares of Blueprint Medicines stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $109.53, for a total value of $1,660,584.33. Following the sale, the director now directly owns 152,396 shares in the company, valued at approximately $16,691,933.88. The trade was a 9.05 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Kate Haviland sold 1,446 shares of Blueprint Medicines stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the sale, the chief executive officer now owns 149,378 shares in the company, valued at approximately $16,467,430.72. This represents a 0.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 29,334 shares of company stock worth $3,103,512. 4.21% of the stock is owned by corporate insiders.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.